XALute trial (xaluritamig): what clinicians have said so far
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
- NCT06691984 ↗
- Active, not recruiting
- Amgen
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on XALute (xaluritamig in metastatic castration-resistant prostate cancer previously treated with chemotherapy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on XALute so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Xaluritamig; Abiraterone; Enzalutamide; Cabazitaxel
- Arms
- Xaluritamig · Experimental
- Cabazitaxel/Abiraterone/Enzalutamide · Active comparator
- Enrollment
- 707
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Amgen
- Start
- Dec 9, 2024
- Primary completion
- Jan 2, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06691984 · updated May 15, 2026